Squamous cell carcinoma of the head and neck
Information
- Disease name
- Squamous cell carcinoma of the head and neck
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03946358 | Active, not recruiting | Phase 2 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | February 18, 2020 | October 2025 |
| NCT01612351 | Active, not recruiting | Phase 2 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | June 2012 | November 2031 |
| NCT03917381 | Active, not recruiting | Phase 1/Phase 2 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | May 14, 2019 | October 2025 |
| NCT03341936 | Active, not recruiting | Phase 2 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | March 15, 2018 | July 6, 2026 |
| NCT04590963 | Active, not recruiting | Phase 3 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | October 2, 2020 | June 28, 2024 |
| NCT03752398 | Active, not recruiting | Phase 1 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | May 1, 2019 | September 2025 |
| NCT06041464 | Active, not recruiting | Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma | March 2, 2021 | March 2, 2024 | |
| NCT04459715 | Active, not recruiting | Phase 3 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | August 7, 2020 | April 30, 2027 |
| NCT03313804 | Active, not recruiting | Phase 2 | Priming Immunotherapy in Advanced Disease With Radiation | October 26, 2017 | February 2025 |
| NCT02841748 | Active, not recruiting | Phase 2 | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | May 10, 2017 | June 25, 2025 |
| NCT02812524 | Active, not recruiting | Phase 1 | Ipilimumab for Head and Neck Cancer Patients | November 18, 2016 | December 2024 |
| NCT02769520 | Active, not recruiting | Phase 2 | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | July 6, 2016 | April 2023 |
| NCT03712566 | Active, not recruiting | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy | November 6, 2018 | December 2024 | |
| NCT03646461 | Active, not recruiting | Phase 2 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | October 17, 2018 | May 30, 2025 |
| NCT04326257 | Active, not recruiting | Phase 2 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | June 5, 2020 | August 12, 2024 |
| NCT02031250 | Active, not recruiting | Phase 2 | Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer | February 2014 | December 2023 |
| NCT02624128 | Active, not recruiting | Phase 2 | Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck | February 23, 2015 | December 2023 |
| NCT03635164 | Active, not recruiting | Phase 1 | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | November 12, 2018 | May 19, 2025 |
| NCT05931445 | Active, not recruiting | N/A | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | January 26, 2021 | March 31, 2027 |
| NCT02573493 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | April 13, 2016 | December 12, 2024 |
| NCT02369458 | Active, not recruiting | Phase 2 | Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies | April 14, 2015 | June 30, 2024 |
| NCT04152018 | Active, not recruiting | Phase 1 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | November 13, 2019 | August 30, 2024 |
| NCT03552965 | Active, not recruiting | N/A | Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC | June 19, 2018 | July 1, 2026 |
| NCT06046625 | Active, not recruiting | Needs and Preferences of Patients With Head-neck Cutaneous SCC | November 1, 2021 | November 30, 2023 | |
| NCT02296684 | Active, not recruiting | Phase 2 | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | March 25, 2015 | December 31, 2025 |
| NCT03381183 | Active, not recruiting | Phase 1 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | August 21, 2019 | December 2024 |
| NCT02105636 | Completed | Phase 3 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | May 29, 2014 | September 10, 2021 |
| NCT02124707 | Completed | Phase 2 | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | June 16, 2014 | October 1, 2019 |
| NCT02158234 | Completed | Phase 1 | Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | July 16, 2014 | August 24, 2021 |
| NCT02262741 | Completed | Phase 1 | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | October 15, 2014 | September 21, 2017 |
| NCT02277197 | Completed | Phase 1 | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | August 2015 | February 2018 |
| NCT02350712 | Completed | Phase 1 | Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | December 2014 | June 2016 |
| NCT00206219 | Completed | Phase 3 | Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) | November 2003 | September 2007 |
| NCT00206752 | Completed | N/A | Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck | August 2004 | February 2015 |
| NCT00210470 | Completed | Phase 2 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | July 2005 | March 2012 |
| NCT00257738 | Completed | Phase 1 | 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | November 2005 | October 2012 |
| NCT00442455 | Completed | Phase 3 | Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck | January 2006 | August 2015 |
| NCT00513383 | Completed | Phase 1 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | April 2006 | October 2012 |
| NCT00625456 | Completed | Phase 1 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | June 2008 | June 2014 |
| NCT00736944 | Completed | Phase 2 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | December 19, 2008 | July 6, 2020 |
| NCT00971932 | Completed | Phase 2 | Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | July 2009 | |
| NCT01012258 | Completed | Phase 3 | Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects | February 2009 | May 2014 |
| NCT01104922 | Completed | Phase 2 | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | December 26, 2007 | July 26, 2018 |
| NCT01177956 | Completed | Phase 3 | A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck | December 2009 | November 2012 |
| NCT01218048 | Completed | Phase 2 | ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | February 2011 | February 14, 2017 |
| NCT01344356 | Completed | Phase 4 | Stereotactic Body Radiotherapy for Head and Neck Tumors | July 2008 | May 2018 |
| NCT01379339 | Completed | Phase 1 | Cabazitaxel - PF Induction Chemotherapy | April 2011 | January 2015 |
| NCT01386632 | Completed | Phase 2 | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma | May 2011 | June 1, 2020 |
| NCT01458392 | Completed | Phase 2 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | October 2011 | September 2015 |
| NCT01528163 | Completed | Phase 2 | Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | February 2012 | November 2014 |
| NCT01716416 | Completed | Phase 1 | Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) | May 31, 2013 | August 31, 2017 |
| NCT01737008 | Completed | Phase 1 | Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck | January 2013 | May 2015 |
| NCT01758731 | Completed | Phase 1 | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History | October 22, 2012 | October 31, 2018 |
| NCT01774760 | Completed | Phase 2 | Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer | March 2013 | September 2016 |
| NCT01783587 | Completed | Phase 1 | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | February 2013 | June 1, 2018 |
| NCT01998542 | Completed | Phase 2 | Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck | January 2016 | November 2017 |
| NCT02002182 | Completed | Phase 2 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | December 2013 | August 1, 2019 |
| NCT02022098 | Completed | N/A | Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial | October 2013 | April 28, 2022 |
| NCT02435602 | Completed | N/A | The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers | December 2013 | January 2017 |
| NCT02454179 | Completed | Phase 2 | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma | May 2015 | July 2018 |
| NCT02473731 | Completed | Phase 1 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | October 2015 | October 10, 2016 |
| NCT02510859 | Completed | N/A | Nutrition and Life QUality Patients With Head and Neck Cancers | December 2010 | |
| NCT02510872 | Completed | N/A | Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection | December 2011 | |
| NCT02543476 | Completed | SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | September 16, 2015 | November 14, 2016 | |
| NCT02551159 | Completed | Phase 3 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer | October 15, 2015 | May 21, 2021 |
| NCT02565758 | Completed | Phase 1 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | September 18, 2015 | March 25, 2019 |
| NCT02575404 | Completed | Phase 1 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | May 16, 2016 | October 10, 2022 |
| NCT02636036 | Completed | Phase 1 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors | January 25, 2016 | October 8, 2021 |
| NCT02707588 | Completed | Phase 2 | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC | May 18, 2016 | October 17, 2022 |
| NCT02762513 | Completed | Phase 2 | Expansion Trial for Axitinib In Head And Neck Cancer | August 30, 2016 | April 9, 2020 |
| NCT02882308 | Completed | Phase 2 | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. | October 20, 2016 | January 10, 2020 |
| NCT02972216 | Completed | Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy | November 2014 | ||
| NCT03057613 | Completed | Phase 2 | The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck | May 10, 2017 | September 9, 2020 |
| NCT03083873 | Completed | Phase 2 | Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | January 9, 2017 | August 8, 2022 |
| NCT03129061 | Completed | Phase 1 | Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | May 1, 2017 | December 1, 2022 |
| NCT03148665 | Completed | Saliva-based Detection of CD44 | April 14, 2017 | May 3, 2022 | |
| NCT03160495 | Completed | Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens | March 29, 2017 | December 30, 2018 | |
| NCT03194373 | Completed | Phase 2 | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | October 12, 2017 | March 17, 2020 |
| NCT03245736 | Completed | Phase 2 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | August 23, 2017 | January 10, 2019 |
| NCT03330249 | Completed | Phase 2 | Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion | December 3, 2015 | May 10, 2021 |
| NCT03349710 | Completed | Phase 3 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | December 15, 2017 | October 14, 2019 |
| NCT03454451 | Completed | Phase 1 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | April 25, 2018 | February 19, 2023 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT03624231 | Completed | Phase 2 | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC | August 15, 2018 | August 17, 2023 |
| NCT03629756 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | July 24, 2018 | September 3, 2021 |
| NCT03633110 | Completed | Phase 1/Phase 2 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | August 29, 2018 | February 28, 2022 |
| NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
| NCT03689192 | Completed | Phase 1 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | December 17, 2018 | January 19, 2022 |
| NCT03723967 | Completed | Phase 2 | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel | May 16, 2019 | March 9, 2024 |
| NCT03733210 | Completed | Phase 1 | Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer | January 7, 2019 | August 9, 2021 |
| NCT03758781 | Completed | Phase 1 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | February 13, 2019 | August 11, 2021 |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT03880396 | Completed | Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN | March 10, 2019 | December 26, 2020 | |
| NCT03894618 | Completed | Phase 1 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | March 26, 2019 | May 4, 2023 |
| NCT04672772 | Completed | Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. | December 18, 2020 | January 17, 2022 | |
| NCT04881045 | Completed | Phase 1 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | August 18, 2021 | October 24, 2023 |
| NCT05068609 | Completed | A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) | August 13, 2020 | October 18, 2021 | |
| NCT05123950 | Completed | A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe | January 1, 2019 | March 19, 2021 | |
| NCT05835804 | Not yet recruiting | Phase 2 | Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers | June 1, 2023 | April 2026 |
| NCT03843671 | Not yet recruiting | Phase 2 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | July 1, 2019 | December 31, 2024 |
| NCT05751512 | Not yet recruiting | Phase 3 | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | March 2023 | December 2025 |
| NCT02572778 | Recruiting | Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer | September 2015 | December 2025 | |
| NCT05930938 | Recruiting | Phase 3 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer | December 12, 2023 | September 2030 |
| NCT03830385 | Recruiting | Phase 2 | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck | February 15, 2019 | February 15, 2026 |
| NCT04830592 | Recruiting | Phase 1 | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck | November 4, 2021 | October 2024 |
| NCT03944915 | Recruiting | Phase 2 | De-Escalation Therapy for Human Papillomavirus Negative Disease | August 26, 2019 | July 1, 2024 |
| NCT05983133 | Recruiting | Phase 1 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | November 14, 2023 | September 30, 2028 |
| NCT02139020 | Recruiting | Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients | February 2013 | January 2033 | |
| NCT03690986 | Recruiting | Phase 1 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | November 1, 2018 | July 26, 2025 |
| NCT04787042 | Recruiting | Phase 1/Phase 2 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | August 6, 2021 | January 30, 2025 |
| NCT06285097 | Recruiting | Phase 1 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | February 8, 2024 | April 29, 2028 |
| NCT04290546 | Recruiting | Phase 1 | CIML NK Cell in Head & Neck Cancer | July 20, 2020 | December 1, 2024 |
| NCT04191460 | Recruiting | Phase 2 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer | July 12, 2022 | March 1, 2025 |
| NCT05208762 | Recruiting | Phase 1 | A Study of SGN-PDL1V in Advanced Solid Tumors | October 25, 2022 | December 31, 2026 |
| NCT05329532 | Recruiting | Phase 1/Phase 2 | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer | April 7, 2022 | June 30, 2026 |
| NCT05459129 | Recruiting | Phase 1/Phase 2 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | April 13, 2023 | August 11, 2024 |
| NCT06223568 | Recruiting | Phase 2 | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer | June 10, 2024 | January 10, 2028 |
| NCT03645928 | Recruiting | Phase 2 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | May 7, 2019 | August 9, 2029 |
| NCT04609566 | Recruiting | Phase 2 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | January 26, 2021 | September 30, 2026 |
| NCT05482880 | Recruiting | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | February 28, 2022 | December 2023 | |
| NCT06236464 | Recruiting | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | September 25, 2023 | March 2026 | |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05783622 | Recruiting | Phase 1 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | April 19, 2023 | October 2027 |
| NCT04659369 | Terminated | Phase 1 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC | September 24, 2020 | October 16, 2023 |
| NCT03179956 | Terminated | Early Phase 1 | Impact of Ribociclib on Head and Neck Squamous Cell Cancer | April 2, 2018 | January 10, 2019 |
| NCT03246685 | Terminated | Phase 2 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | November 8, 2017 | April 13, 2018 |
| NCT01732640 | Terminated | Phase 1/Phase 2 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | December 2012 | January 2017 |
| NCT01488318 | Terminated | Phase 2 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | September 2011 | August 2016 |
| NCT03513042 | Terminated | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck | January 21, 2021 | November 23, 2022 | |
| NCT03525392 | Terminated | Phase 1 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | May 3, 2018 | April 28, 2021 |
| NCT01415986 | Terminated | Phase 2 | Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers | November 2010 | March 2012 |
| NCT01360827 | Terminated | Phase 1 | EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck | August 2010 | |
| NCT01305772 | Terminated | Phase 2 | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN | January 2011 | May 2012 |
| NCT01221753 | Terminated | Phase 2 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | July 2011 | July 2017 |
| NCT00570674 | Terminated | Phase 1/Phase 2 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | November 2007 | October 2013 |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT02429089 | Terminated | Phase 1 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck | April 2015 | September 1, 2018 |
| NCT03862066 | Terminated | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | February 8, 2019 | November 22, 2021 | |
| NCT02437916 | Terminated | Phase 1 | Safety Study of AMG 228 to Treat Solid Tumors | April 21, 2015 | December 12, 2016 |
| NCT02452424 | Terminated | Phase 1/Phase 2 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | July 2, 2015 | October 12, 2018 |
| NCT00377247 | Terminated | Phase 1 | Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor | April 2009 | April 2009 |
| NCT01051791 | Terminated | Phase 2 | Phase II Study of RAD001 Head and Neck Cancer | January 2010 | August 5, 2016 |
| NCT02538627 | Terminated | Phase 1 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | August 2015 | October 5, 2016 |
| NCT01015664 | Terminated | Phase 1/Phase 2 | Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | February 2010 | December 2012 |
| NCT04034225 | Terminated | Phase 1/Phase 2 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | November 11, 2019 | June 28, 2021 |
| NCT02124850 | Terminated | Phase 1 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | October 28, 2014 | October 31, 2016 |
| NCT02628535 | Terminated | Phase 1 | Safety Study of MGD009 in B7-H3-expressing Tumors | September 2015 | November 25, 2019 |
| NCT00903461 | Terminated | Phase 1 | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | April 2012 | August 2016 |
| NCT01984892 | Terminated | Phase 2 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) | November 2013 | August 2014 |
| NCT02819752 | Terminated | Phase 1 | PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | July 12, 2017 | November 28, 2019 |
| NCT04453046 | Terminated | N/A | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | October 22, 2020 | November 14, 2022 |
| NCT02952586 | Terminated | Phase 3 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | November 28, 2016 | August 25, 2020 |
| NCT00901537 | Terminated | Phase 1 | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | February 2009 | October 2011 |
| NCT04628780 | Terminated | Phase 1 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | December 16, 2020 | May 26, 2023 |
| NCT00272181 | Terminated | Phase 2 | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | January 2006 | October 2007 |
| NCT00999700 | Unknown status | Phase 3 | Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin | September 2009 | December 2021 |
| NCT02054442 | Unknown status | Phase 1/Phase 2 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck | August 2016 | December 2022 |
| NCT03139058 | Unknown status | N/A | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck | August 20, 2018 | June 20, 2019 |
| NCT02352792 | Unknown status | N/A | Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer | December 2008 | December 2022 |
| NCT03071900 | Unknown status | N/A | CTC Detection Rate in SCCHN With a in Vivo Device | June 22, 2016 | April 20, 2017 |
| NCT00652613 | Unknown status | Phase 2 | Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | August 2005 | August 2009 |
| NCT03938012 | Unknown status | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | October 3, 2017 | October 2022 | |
| NCT03076372 | Unknown status | Phase 1 | A Study Evaluating MM-310 in Patients With Solid Tumors | February 22, 2017 | December 2018 |
| NCT03855384 | Unknown status | Phase 3 | Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） | June 11, 2019 | May 30, 2021 |
| NCT01830556 | Unknown status | Phase 2 | Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck | November 2011 | November 2015 |
| NCT03202173 | Unknown status | N/A | The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy | January 1, 2017 | June 30, 2018 |
| NCT02765503 | Unknown status | N/A | Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial | March 2014 | November 2021 |
| NCT03098160 | Unknown status | Phase 1 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | May 10, 2017 | April 2019 |
| NCT02686008 | Withdrawn | Phase 1 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | January 2018 | July 2019 |
| NCT01967927 | Withdrawn | Early Phase 1 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy | December 2013 | August 17, 2021 |
| NCT01133262 | Withdrawn | Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device | June 2010 | December 2011 | |
| NCT03325465 | Withdrawn | Phase 2 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | January 22, 2018 | November 7, 2018 |
| NCT01820312 | Withdrawn | Phase 2 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | January 2013 | July 2015 |